Skip to main content

Board of Directors

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Mr. Mark Nawacki

Mr. Mark Nawacki

Chairman

Mr. Mark Nawacki is the president and CEO of Searchlight Pharma. Prior to this, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, a leading Canadian specialty pharmaceutical company, from 2003 - 2014. Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), MBA also from the University of Toronto, and is a Canadian-designated CPA. He is a past member of the Board of Trustees of the Licensing Executive Society (USA & Canada) and is a former President and Board Member of the Canadian Healthcare Licensing Association. He also currently sits on the Board of the Montreal Bach Festival and The Sacred Heart School of Montreal.

Marc Edwards

Marc Edwards

Director, Interim Chief Executive Officer

Mr. Edwards is the founder and President of VetRx, a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr. Edwards holds a Bachelor's degree (Finance) from l'Université de Sherbrooke and an MBA from Concordia University.

Rashieda Gluck

Rashieda Gluck

Director

Ms. Gluck currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its Vice President of Clinical Operations since January 1, 2016. She previously served as Vice President of Clinical Operations at Qu Biologics Inc., where she led the clinical development of their platform immunotherapeutic treatments.  Prior to that, Ms. Gluck served as Vice President and Head of Global Clinical Operations at Vifor Pharmaceuticals, based in Zurich Switzerland post acquisition of Aspreva Pharmaceuticals where she was Vice President of Clinical Operations.  In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK. Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.

Dr. Allan Mandelzys

Director

Dr Mandelzys, who has been instrumental in the growth of several biotechnology and pharmaceutical companies, is a strategic business and scientific consultant to the biotech industry. He is currently Chairman of Searchlight Pharma and a member of the Board of Matrizyme Pharma Corp and Exactis Innovation. He is a former Board member of Clementia Pharmaceuticals up until its acquisition by Ipsen in 2019 and of Bedrocan Cannabis Corporation up until its amalgamation into Canopy Growth Corporation in 2015. Prior to his consulting roles, Dr. Mandelzys served as CEO and director at Thallion Pharmaceuticals up until its acquisition by Bellus Health in 2013. Prior to Thallion, Dr. Mandelzys served as vice president of business development at Labopharm from 2000 to 2006 and held senior research and business development roles with Allelix Biopharmaceuticals from 1995 to 2000 through its acquisition by NPS Pharmaceuticals. Dr. Mandelzys earned a PhD in physiology and an MBA from McGill University, and holds a BSc from the University of Toronto. He received his post-doctoral training at the Roche Institute of Molecular Biology.